PT  - JOURNAL ARTICLE
AU  - Chiang, Silvia S.
AU  - Romanowski, Kamila
AU  - Johnston, James C.
AU  - Petiquan, Alex
AU  - Bastos, Mayara
AU  - Menzies, Dick
AU  - Land, Sierra
AU  - Benedetti, Andrea
AU  - Khan, Faiz Ahmad
AU  - van der Zalm, Marieke M.
AU  - Campbell, Jonathon R.
TI  - Tuberculosis-Associated Respiratory Disability in Children, Adolescents, and Adults: Protocol for a Systematic Review and Individual Participant Data Meta-Analysis
AID  - 10.1101/2024.09.03.24313003
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.03.24313003
4099  - http://medrxiv.org/content/early/2024/09/04/2024.09.03.24313003.short
4100  - http://medrxiv.org/content/early/2024/09/04/2024.09.03.24313003.full
AB  - Background Approximately 2% of the global population has survived tuberculosis (TB). Increasing evidence indicates that a significant proportion of pulmonary TB survivors develop TB-associated respiratory disability, commonly referred to as post-TB lung disease (PLTD) and marked by impaired respiratory function, persistent symptoms, and activity limitations. However, the prevalence, risk factors, and progression of TB-associated respiratory disability throughout the life course are not well understood. To address these gaps, we will undertake a systematic review and individual participant-level data meta-analysis (IPD-MA) focusing on TB-associated respiratory disability in children, adolescents, and adults successfully treated for pulmonary TB.Methods and analysis We will systematically search MEDLINE, Embase, CENTRAL, Global Index Medicus, and medRxiv for original studies investigating TB-associated respiratory disability in people of all ages who have completed treatment for microbiologically confirmed or clinically diagnosed pulmonary TB. Authors of eligible studies will be invited to contribute de-identified data and form a collaborative group. Primary outcomes will be (1) abnormal lung function based on spirometry parameters and (2) chronic respiratory symptoms. We will estimate the overall and subgroup-specific prevalence of each outcome through IPD meta-analysis. Next, we will develop clinical prediction tools assessing the risk of future TB-associated respiratory disability at (i) the start of TB treatment and (ii) end of TB treatment for those without existing signs of disability. Finally, we will use stepwise hierarchical modelling to identify epidemiological determinants of respiratory disability.Ethics and dissemination This study has been approved by the ethics review boards at the Rhode Island Hospital (2138217-2) and the Research Institute of the McGill University Health Centre (2024-10345). Individual study authors will be required to obtain institutional approval prior to sharing data. Results will be disseminated through open-access, peer-reviewed publications and conference presentations.Prospero registration number CRD42024529906Strengths and limitations of this studyAn individual participant data meta-analysis allows for data harmonization to help overcome limitations of individual studies and aggregate meta-analysis, including small sample size, heterogeneity, and limited reporting of subgroups, such as age and other risk factors.We will be able to identify weaknesses in current reporting and recommend standards to support high-quality data collection and facilitate pooling of data.Key limitations include authors’ willingness to share data, representativeness of data contributed, and missing data.We will build an ongoing data collection platform to allow updating of evidence.Results will have implications for public health, clinical trial design, and clinical practice to support TB survivors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the Robert E. Leet & Clara Guthrie Patterson Trust (United States, PI Silvia S. Chiang) and the Canadian Institutes of Health Research (Canada, PI Jonathon R. Campbell; PJT-195781). The funders had no role in developing this protocol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the ethics review boards at the Rhode Island Hospital (2138217-2) and the Research Institute of the McGill University Health Centre (2024-10345). Individual study authors will be required to obtain institutional approval prior to sharing data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors